Table 2.
Analysis of correlations between chitotriosidase and YKL-40 peripheral blood levels and clinical parameters in patients with COPD
| Chitotriosidase serum concentration | Chitotriosidase serum activity | Chitotriosidase PBMC mRNA expression | YKL-40 serum concentration | YKL-40 PBMC mRNA expression | |
|---|---|---|---|---|---|
| Age | R=−0.10 P=0.50 |
R=−0.19 P=0.22 |
R=−0.11 P=0.48 |
R=0.14 P=0.37 |
R=0.04 P=0.81 |
| Time since diagnosis | R=−0.10 P=0.50 |
R=−0.19 P=0.21 |
R=−0.27 P=0.09 |
R=0.14 P=0.37 |
R=0.34 P=0.03 |
| Pack-years | R=0.04 P=0.76 |
R=0.01 P=0.96 |
R=0.31 P=0.04 |
R=−0.02 P=0.88 |
R=0.17 P=0.27 |
| FEV1% predicted | R=0.00 P=0.99 |
R=−0.00 P=0.97 |
R=0.01 P=0.93 |
R=0.00 P=0.99 |
R=−0.12 P=0.43 |
| FEV1/FVC% | R=0.06 P=0.67 |
R=0.16 P=0.32 |
R=−0.11 P=0.48 |
R=−0.07 P=0.64 |
R=0.10 P=0.53 |
| BMI | R=−0.21 P=0.19 |
R=−0.25 P=0.11 |
R=0.04 P=0.77 |
R=−0.09 P=0.56 |
R=0.05 P=0.74 |
| CAT | R=−0.18 P=0.25 |
R=−0.16 P=0.32 |
R=0.02 P=0.87 |
R=−0.27 P=0.08 |
R=−0.17 P=0.26 |
| mMRC | R=−0.16 P=0.29 |
R=−0.22 P=0.16 |
R=0.00 P=0.96 |
R=−0.09 P=0.56 |
R=−0.24 P=0.12 |
| 6MWT | R=0.07 P=0.63 |
R=0.05 P=0.73 |
R=0.08 P=0.59 |
R=0.02 P=0.86 |
R=0.05 P=0.74 |
| BODE | R=−0.04 P=0.78 |
R=0.01 P=0.96 |
R= −0.10 P=0.52 |
R=0.09 P=0.57 |
R=0.11 P=0.46 |
| Sputum macrophages, % | R=−0.07 P=0.63 |
R=0.06 P=0.67 |
R=0.00 P=0.98 |
R=−0.26 P=0.09 |
R=−0.07 P=0.63 |
| Sputum neutrophils, % | R=0.19 P=0.22 |
R=0.00 P=0.99 |
R=0.11 P=0.49 |
R=0.40 P=0.01 |
R=0.22 P=0.16 |
| Sputum lymphocytes, % | R=−0.00 P=0.98 |
R=−0.03 P=0.82 |
R=−0.06 P=0.69 |
R=−0.28 P=0.07 |
R=−0.12 P=0.46 |
| Sputum eosinophils, % | R=−0.12 P=0.45 |
R=0.07 P=0.66 |
R=−0.06 P=0.72 |
R=0.12 P=0.42 |
R=−0.06 P=0.72 |
Notes: BODE index, BMI, airway obstruction, dyspnea, exercise capacity.
Abbreviations: PBMC, peripheral blood mononuclear cells; BMI, body mass index CAT, COPD Assessment Test; mMRC, modified Medical Research Council dyspnea scale; 6MWT, six-minute walk test.